PHS II Trial: Use of multivitamins in the prevention of cardiovascular disease in men.

Observational studies have shown contradicting results on the use of multivitamins. PHS II is the only randomized double blind placebo controlled trial to evaluate the long term effect of the use of multivitamins in the prevention of CVD. 14,641 physicians ≥50 were randomized in 1997 to receive placebo or an E, C and Centrum Silver multivitamin on a daily basis. Primary end point was CVD or cancer occurrence. At 11,2 year follow up, primary end point showed no differences between the two groups. Considered separately, cancer was 8% less frequent in the multivitamin group.

Conclusion: multivitamin supplements did not reduce cardiovascular events in the studied population.

Comment: the use of multivitamins must be considered to treat nutritional deficiencies and not to prevent cardiovascular disease. Effect of multivitamins on cancer occurrence is modest.

7_sidney_smith
Sidney Smith
2012-11-05

Original title: PHS II Trial: A Multivitamin in the Prevention of CVD in Men.

More articles by this author

GAUSS trial: Antibodies for the treatment of hypercholesterolemia in patients with statin intolerance.

Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are statin intolerant or present adverse effects at...

DALCETRAPIB: Dalcetrabib for the treatment of ACS

High levels of HDL are known to exert a protective effect. In previous studies, dalcetrapib administration increased HDL 30% from baseline. The objective was...

Monoclonal antibodies for the treatment of dislipidemia in patients on maximal dose statins.

Statins are first-line therapy for hypercholesterolemia. However, many patients are not able to achieve their goals despite the maximal dose or because of adverse...

FORWARD Trial: Use of Omega 3 to prevent recurring atrial fibrillation

Atrial fibrillation (AF) is a very prevalent arrhythmia and there is no known drug, device or ablation technique effective enough to treat it. Omega...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...